The new year has ushered in a flow of biotech-specific funds, including $700 million from Andreessen Horowitz (A16z). | The ...

Leerink, however, has questioned the company’s direction. In a note to clients sent out Jan. 8, the analysts said they ...

Meanwhile, another $70 million to $80 million of the IPO proceeds is expected to fund the launch a phase 1b study of its ...

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the ...

In return for the rights to YL201 outside China, MediLink will receive upfront and potential near-term milestone payments ...

A new year brings a fresh Fierce Biotech Fundraising Tracker designed to record the significant amount of venture capital ...

After unsheathing just a few months ago, Ollin Biosciences’ next-gen bispecific antibody cleared more disease faster than ...

Madrigal has paid Pfizer $50 million for the rights to a DGAT2i inhibitor with the intention of combining the drug with its ...

It sounds like Lilly did just that. The U.S. pharma announced Wednesday that it was paying $14 per share of Ventyx—more than ...

AirNexis has handed over $40 million cash for Haisco’s HSK39004, coded by AirNexis as AN01. Under the terms of the deal, ...

Menlo Ventures has made a $16 million bet that the “ baby KJ ” custom CRISPR therapy success story is repeatable. The funding ...

EpiBiologics launched in 2023 with a $50 million series A, having been founded to take forward the work of renowned antibody ...